Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Adverse Effects of Olaparib in Ovarian Cancer: a Prospective Real-world Product Registration Study.

NCT04699006 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT04699006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04699006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Adverse Effects of Olaparib in Ovarian Cancer: a Prospective Real-world Product Registration Study.
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Observational
Overall status
Unknown status
Start date
January 21, 2021
Completion date
January 1, 2026
Enrollment
245 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer